Singapore, May 13 -- US-based LENZ Therapeutics, Inc. and Taiwan's Lotus Pharmaceutical have announced an exclusive license and commercialisation agreement for Lotus to commercialise LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia.

LENZ Therapeutics is a pre-commercial stage biopharmaceutical company focused on the development and commercializsation of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia. Lotus is a leading global pharmaceutical company focused on commercializsing novel pharmaceuticals to provide patients with better, safer and more accessible medicines.

Under the terms of the licensing and commercialization agreement, LENZ ...